troglitazone has been researched along with Insulin Resistance in 220 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to assess the usefulness of a model-based index of insulin sensitivity during an oral glucose tolerance test (OGTT) in the identification of possible changes in this metabolic parameter produced by pharmacological agents known to be potent insulin sensitizers, that is metformin (M) and thiazolidinedione (T)." | 9.12 | Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. ( Hanusch-Enserer, U; Kautzky-Willer, A; Ludvik, B; Pacini, G; Prager, R; Tura, A; Wagner, OF; Winzer, C, 2006) |
| "To examine the effects of troglitazone, an agent used to treat insulin resistance, on cardiac sympathetic nervous dysfunction and insulin resistance in patients with essential hypertension." | 9.11 | Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. ( Hamada, M; Ikeda, S; Inaba, S; Kohara, K; Komatsu, J; Kurata, M; Sueda, S; Suzuki, J; Watanabe, K, 2004) |
| " Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients." | 9.10 | Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003) |
| "The study was undertaken to assess the long-term cardiovascular effects of troglitazone on non-diabetic individuals with insulin resistance." | 9.10 | Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. ( Boudoulas, H; Osei, K; Schuster, DP; Sparks, EA; Stakos, DA; Wooley, CF, 2003) |
| "To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels." | 9.10 | Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| "We hypothesized that the administration of troglitazone (TGZ), an insulin-sensitizing agent of the thiazolidinedione class, would improve dyslipidemia associated with insulin resistance in polycystic ovary syndrome (PCOS)." | 9.10 | Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| "To investigate the effect of troglitazone, a new antidiabetic agent that improves insulin resistance, on endocrine, metabolic, and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome (PCOS)." | 9.09 | Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. ( Hasegawa, I; Kurabayashi, T; Murakawa, H; Suzuki, M; Tanaka, K; Yamamoto, Y, 1999) |
| "Troglitazone promotes adipocyte differentiation in vitro and increases insulin sensitivity in vivo." | 9.09 | Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. ( Arioglu, E; Duncan-Morin, J; Gottlieb, N; Herion, D; Hoofnagle, J; Kleiner, DE; Lieberman, J; Premkumar, A; Reitman, ML; Reynolds, J; Rother, KI; Sebring, N; Sumner, AE; Taylor, SI, 2000) |
| " Troglitazone (CS-045) is a newly developed antidiabetic agent that enhances insulin sensitivity." | 9.08 | Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. ( Ikegami, H; Masuo, K; Mikami, H; Ogihara, T; Rakugi, H, 1995) |
| "Troglitazone decreases insulin resistance and hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM), but its effects on subjects without diabetes are not known." | 9.07 | Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. ( Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J, 1994) |
| " Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus." | 8.80 | Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998) |
| " Troglitazone, one of the thiazolidinediones, improves not only insulin sensitivity but also hyperandrogenism and ovulatory function." | 8.80 | [Troglitazone for treatment of polycystic ovary syndrome]. ( Iwamoto, Y; Sanaka, M, 2000) |
| "Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods." | 7.71 | Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002) |
| "Both metformin and troglitazone were comparably effective in reducing insulin resistance." | 7.71 | Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats. ( Chang, CT; Chen, CC; Chen, RH; Sheen, LY; Shih, HC; Wang, HJ; Wang, TY, 2001) |
| " When results for patients with and without hypertension were separately analyzed, a significant improvement in SMGU after troglitazone was seen in both normotensive and hypertensive patients (normotensive [n = 10]: baseline, 3." | 7.71 | Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients. ( Inoue, Y; Momose, T; Moritan, T; Nagai, R; Ohtomo, K; Tateno, M; Yokoyama, I; Yonekura, K, 2001) |
| "It is well known that troglitazone and voluntary running have the capacity to improve insulin resistance." | 7.71 | Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat. ( Han, YQ; Kitakoshi, K; Nakai, N; Oshida, Y; Sato, Y, 2001) |
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 7.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| "Troglitazone, a thiazolidinedione derivative, has been shown to counteract insulin resistance in obesity and non-insulin-dependent diabetes mellitus (NIDDM)." | 7.70 | Effects of troglitazone on dexamethasone-induced insulin resistance in rats. ( Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1998) |
| "In order to study the effects of troglitazone on insulin resistance associated with elevated plasma free fatty acid (FFA), the hindquarters of rats treated with troglitazone for 14 days were perfused with a medium containing 15 mmol/l glucose, 0-1,000 microU/ml insulin, and 0 or 1." | 7.70 | Troglitazone reduces free fatty acid-induced insulin resistance in perfused rat hindquarter. ( Mokuda, O; Sakamoto, Y, 1998) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 7.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy." | 7.70 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. ( Elkind-Hirsch, KE; McWilliams, RB, 1999) |
| " We studied whether pretreatment with these compounds can prevent the deleterious effects of glucosamine on insulin action that may play an important role in hyperglycemia-induced insulin resistance." | 7.70 | Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats. ( Hattori, J; Kawachi, S; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1999) |
| "Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects." | 7.69 | Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995) |
| "Troglitazone is a new orally active hypoglycemic agent that has been shown to reduce insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects." | 7.69 | Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1994) |
| "Troglitazone, a newly developed oral antidiabetic agent, improves hyperglycemia, and has been reported to improve insulin resistance and to decrease hepatic glucose production in diabetic animals." | 7.69 | Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. ( Higa, S; Ishikawa, K; Mimura, G; Murakami, K; Takasu, N; Yagi, N, 1995) |
| "Troglitazone is a newly developed antidiabetic drug that has been shown to improve insulin resistance and hyperinsulinemia both in diabetic animal models and in patients with non-insulin-dependent diabetes mellitus." | 7.69 | Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis. ( Arakawa, K; Saku, K; Zhang, B, 1997) |
| " Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]." | 7.69 | Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. ( Cavaghan, MK; Ehrmann, DA; Imperial, J; Polonsky, KS; Rosenfield, RL; Schneider, DJ; Sobel, BE, 1997) |
| "A total of 34 subjects with type 2 diabetes (17 men and 17 women, aged 54+/-2 years and body mass index (BMI) 26." | 6.71 | Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. ( Ishibashi, S; Ishikawa, SE; Kusaka, I; Nagasaka, S; Nakamura, T; Yatagai, T; Yoshitaka, A, 2004) |
| "Troglitazone treatment resulted in a decrease in fasting plasma glucose from 11." | 6.69 | Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. ( Kahn, SE; Porte, D; Prigeon, RL, 1998) |
| "Insulin resistance is associated with a decreased vasodilator response to insulin." | 6.69 | Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. ( Lutterman, JA; Ong, MK; Smits, P; Tack, CJ, 1998) |
| "The management of Type 2 diabetes mellitus with currently available oral agents may be complicated in the elderly by an increased frequency of side-effects." | 6.69 | Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. ( Barnett, AH; Kumar, S; Lettis, S; Prange, A; Schulze, J, 1998) |
| "Insulin resistance is associated with atherogenic lipoprotein phenotype, including small dense LDL particle, hypertriglycemia and low HDL cholesterol levels." | 6.69 | Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. ( Daida, H; Mokuno, H; Ohmura, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 1999) |
| "Treatment with troglitazone 400 mg q." | 6.69 | Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. ( Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R, 2000) |
| "Insulin resistance is thought to lead to overproduction of very low-density lipoprotein (VLDL) cholesterol through the decreased peripheral lipoprotein lipase (LPL) activity, increased production of apolipoprotein B-100 and decreased clearance of remnant particles." | 6.41 | [Dyslipidemia in insulin resistance and its improvement by troglitazone]. ( Mabuchi, H; Yagi, K, 2000) |
| "This finding suggests that primary treatment of insulin resistance could prevent the development of atherosclerosis by improving endothelial dysfunction." | 5.31 | Troglitazone improves endothelial dysfunction in patients with insulin resistance. ( Daida, H; Hoshi, S; Iwama, Y; Mokuno, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 2000) |
| "Insulin resistance in Werner's syndrome (WS) is probably due to defective signaling distal to the insulin receptor." | 5.30 | Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. ( Akazawa, S; Chikuba, N; Ishibashi, M; Izumino, K; Matsumoto, K; Nagataki, S; Sakamaki, H; Takino, H; Tokuyama, K; Yamaguchi, Y; Yamasaki, H, 1997) |
| "Troglitazone treatment completely prevented the TNF-alpha-induced decline in submaximal GDR (133 +/- 16 vs." | 5.30 | TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. ( Cohen, A; Higo, K; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1997) |
| "Troglitazone treatment largely prevented the hyperglycemia-induced decline in submaximal (116 +/- 7 micromol x kg(-1) x min[-1]) and maximal GDR (209 +/- 9 micromol x kg(-1) x min(-1); P < 0." | 5.30 | Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. ( Higo, K; Lee, MK; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1998) |
| "Troglitazone was given at 100 mg/kg/d orally for 5 days before and 2 days during rhGH." | 5.30 | Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats. ( Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1998) |
| "Troglitazone was obtained in 5 steps from 4-bromo-1,1-dimethoxy-3-methylbut-2-ene with an overall yield of 7." | 5.30 | A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance. ( Cossy, J; Desmurs, JR; Kahn, PH; Menciu, C; Rakotoarisoa, H, 1999) |
| "This study was designed to assess the usefulness of a model-based index of insulin sensitivity during an oral glucose tolerance test (OGTT) in the identification of possible changes in this metabolic parameter produced by pharmacological agents known to be potent insulin sensitizers, that is metformin (M) and thiazolidinedione (T)." | 5.12 | Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. ( Hanusch-Enserer, U; Kautzky-Willer, A; Ludvik, B; Pacini, G; Prager, R; Tura, A; Wagner, OF; Winzer, C, 2006) |
| "To examine the effects of troglitazone, an agent used to treat insulin resistance, on cardiac sympathetic nervous dysfunction and insulin resistance in patients with essential hypertension." | 5.11 | Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. ( Hamada, M; Ikeda, S; Inaba, S; Kohara, K; Komatsu, J; Kurata, M; Sueda, S; Suzuki, J; Watanabe, K, 2004) |
| " Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients." | 5.10 | Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003) |
| "The study was undertaken to assess the long-term cardiovascular effects of troglitazone on non-diabetic individuals with insulin resistance." | 5.10 | Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. ( Boudoulas, H; Osei, K; Schuster, DP; Sparks, EA; Stakos, DA; Wooley, CF, 2003) |
| "To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels." | 5.10 | Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| "We hypothesized that the administration of troglitazone (TGZ), an insulin-sensitizing agent of the thiazolidinedione class, would improve dyslipidemia associated with insulin resistance in polycystic ovary syndrome (PCOS)." | 5.10 | Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| "To investigate the effect of troglitazone, a new antidiabetic agent that improves insulin resistance, on endocrine, metabolic, and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome (PCOS)." | 5.09 | Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. ( Hasegawa, I; Kurabayashi, T; Murakawa, H; Suzuki, M; Tanaka, K; Yamamoto, Y, 1999) |
| "Troglitazone promotes adipocyte differentiation in vitro and increases insulin sensitivity in vivo." | 5.09 | Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. ( Arioglu, E; Duncan-Morin, J; Gottlieb, N; Herion, D; Hoofnagle, J; Kleiner, DE; Lieberman, J; Premkumar, A; Reitman, ML; Reynolds, J; Rother, KI; Sebring, N; Sumner, AE; Taylor, SI, 2000) |
| " Troglitazone (CS-045) is a newly developed antidiabetic agent that enhances insulin sensitivity." | 5.08 | Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. ( Ikegami, H; Masuo, K; Mikami, H; Ogihara, T; Rakugi, H, 1995) |
| "Troglitazone treatment improved insulin sensitivity." | 5.08 | Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. ( Demacker, PN; Smits, P; Stalenhoef, AF; Tack, CJ, 1998) |
| "Troglitazone, which improves peripheral insulin resistance of experimental diabetic animals and diabetic patients, affects ob gene expression in the adipose tissue of rodents." | 5.08 | Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. ( Kobayashi, I; Mori, M; Sato, N; Shimizu, H; Shimomura, Y; Tsuchiya, T, 1998) |
| "Troglitazone decreases insulin resistance and hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM), but its effects on subjects without diabetes are not known." | 5.07 | Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. ( Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J, 1994) |
| " Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus." | 4.80 | Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "Insulin resistance is a major component of type 2 diabetes; therefore, an insulin sensitizer agent like the thiazolidinedione compound troglitazone is considered a very promising drug." | 4.80 | Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. ( Lefèbvre, PJ; Scheen, AJ, 1999) |
| "Troglitazone, a newly introduced insulin sensitizer, has been implicated in prevention and treatment of atherosclerotic cardiovascular disease especially associated with type 2 diabetes mellitus and insulin resistance." | 4.80 | [Cardiovascular effects of the thiazolidinedione troglitazone]. ( Kuzuya, H; Nakano, T; Yamada, K, 2000) |
| " Troglitazone, one of the thiazolidinediones, improves not only insulin sensitivity but also hyperandrogenism and ovulatory function." | 4.80 | [Troglitazone for treatment of polycystic ovary syndrome]. ( Iwamoto, Y; Sanaka, M, 2000) |
| " Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss." | 4.79 | [Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| " Insulin resistance was induced in theca cells without (Con) or with dexamethasone (Dex); cells were further treated by troglitazone (Tro) and metformin (Met) in IR cells or by vehicle only in IR and Con cells." | 3.75 | Insulin resistance directly contributes to androgenic potential within ovarian theca cells. ( Erkkola, R; Gao, L; Hou, L; Qu, J; Wang, Y; Wu, X, 2009) |
| " Troglitazone attenuated HOMA-IR and ameliorated proteinuria, but did not affect body weight, creatinine clearance, or blood pressure." | 3.73 | Insulin resistance contributes to obesity-related proteinuria. ( Iwasawa, H; Matsumoto, H; Nagaoka, Y; Nakao, T; Okada, T; Tomaru, R; Wada, T, 2005) |
| "Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods." | 3.71 | Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002) |
| "Both metformin and troglitazone were comparably effective in reducing insulin resistance." | 3.71 | Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats. ( Chang, CT; Chen, CC; Chen, RH; Sheen, LY; Shih, HC; Wang, HJ; Wang, TY, 2001) |
| " When results for patients with and without hypertension were separately analyzed, a significant improvement in SMGU after troglitazone was seen in both normotensive and hypertensive patients (normotensive [n = 10]: baseline, 3." | 3.71 | Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients. ( Inoue, Y; Momose, T; Moritan, T; Nagai, R; Ohtomo, K; Tateno, M; Yokoyama, I; Yonekura, K, 2001) |
| "It is well known that troglitazone and voluntary running have the capacity to improve insulin resistance." | 3.71 | Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat. ( Han, YQ; Kitakoshi, K; Nakai, N; Oshida, Y; Sato, Y, 2001) |
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 3.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| "We sought to ascertain whether pretreatment with troglitazone (20 days) could prevent acute free fatty acid (FFA)-induced insulin resistance in male Wistar rats." | 3.71 | Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. ( Hevener, AL; Janez, A; Olefsky, J; Reichart, D, 2001) |
| "To examine the effect of chronic oral administration of troglitazone on the age-related changes of insulin resistance, plasma CCK levels, and pancreatic growth in normal rats." | 3.71 | Troglitazone stimulates pancreatic growth in normal rats. ( Jia, DM; Otsuki, M, 2002) |
| "We studied the effect of troglitazone on the plasma concentrations of homocysteine (tHcy), the erythrocyte and hepatic concentrations of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH), and the hepatic activities of cystathionine-beta-synthase (C beta S) and methylenetetrahydrofolate reductase (MTHFR) in lean and fatty Zucker rats (a model of insulin resistance)." | 3.71 | The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. ( Desouza, C; Dicker-Brown, A; Fonseca, V; Keebler, M; McNamara, DB; Murthy, SN; Poirier, LA, 2002) |
| "Troglitazone, a thiazolidinedione derivative, has been shown to counteract insulin resistance in obesity and non-insulin-dependent diabetes mellitus (NIDDM)." | 3.70 | Effects of troglitazone on dexamethasone-induced insulin resistance in rats. ( Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1998) |
| "Troglitazone, a thiazolidinedione derivative, overcomes insulin resistance through promoting insulin receptor function." | 3.70 | Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. ( Funahashi, T; Kameda-Takemura, K; Kihara, S; Matsuzawa, Y; Nakamura, T; Ouchi, N; Shinohara, E; Yamashita, S, 1998) |
| "The thiazolidinedione analogue troglitazone is an antidiabetic agent that improves insulin resistance in rodents and humans." | 3.70 | Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. ( Funahashi, T; Kihara, S; Matsuzawa, Y; Ouchi, N; Shinohara, E; Tamura, R; Yamashita, S, 1998) |
| "The thiazolidinediones troglitazone and BRL 49653 improve insulin sensitivity in humans and animals with insulin resistance." | 3.70 | Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. ( Kern, PA; Ranganathan, S, 1998) |
| "In order to study the effects of troglitazone on insulin resistance associated with elevated plasma free fatty acid (FFA), the hindquarters of rats treated with troglitazone for 14 days were perfused with a medium containing 15 mmol/l glucose, 0-1,000 microU/ml insulin, and 0 or 1." | 3.70 | Troglitazone reduces free fatty acid-induced insulin resistance in perfused rat hindquarter. ( Mokuda, O; Sakamoto, Y, 1998) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 3.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "To determine whether hypoglycemic agents such as sulfonylureas, biguanides and the newly developed insulin sensitizers such as troglitazone, have hypotensive effects in an animal model of non-insulin-dependent diabetes mellitus associated with insulin resistance, male Otsuka Long Evans Tokushima Fatty (OLETF) rats aged 12 weeks were administered following hypoglycemic agents or vehicle by gavage for 26 weeks; glibenclamide (5 mg/kg/day), metformin (100 mg/kg/day) and troglitazone (70 mg/kg/day)." | 3.70 | Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats. ( Awata, T; Chen, S; Katayama, S; Kosegawa, I; Negishi, K, 1999) |
| "To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy." | 3.70 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. ( Elkind-Hirsch, KE; McWilliams, RB, 1999) |
| " We studied whether pretreatment with these compounds can prevent the deleterious effects of glucosamine on insulin action that may play an important role in hyperglycemia-induced insulin resistance." | 3.70 | Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats. ( Hattori, J; Kawachi, S; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1999) |
| "Obesity is often accompanied by a decreased ability of insulin to stimulate glucose uptake and glycogenesis in skeletal muscle." | 3.70 | Assessment of human muscle glycogen synthesis and total glucose content by in vivo 13C MRS. ( Heerschap, A; Smits, P; Tack, CJ; Van Den Bergh, AJ; Van Den Boogert, HJ; Vervoort, G, 2000) |
| " We tested the hypothesis that troglitazone, which improves insulin sensitivity and lowers plasma insulin levels in insulin-resistant obese subjects and patients with type 2 diabetes, would also lower circulating PAI-1 antigen concentrations and activity." | 3.70 | Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. ( Kruszynska, YT; Olefsky, JM; Sobel, BE; Yu, JG, 2000) |
| " The aim was to define the insulin-sensitizing effects of S15261, the cleavage products, and troglitazone and metformin in the JCR:LA-cp rat, an animal model of the obesity/insulin resistance syndrome that exhibits an associated vasculopathy and cardiovascular disease." | 3.70 | Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. ( Brindley, DN; Davidge, ST; Delrat, P; Jochemsen, R; Kelly, SE; O'Brien, SF; Pégorier, JP; Ravel, D; Russell, JC, 2000) |
| "An open study comparing the effects of weight reduction by low-energy diet and treatment with troglitazone, an insulin-sensitizing agent." | 3.70 | Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients. ( Kawano, Y; Minami, J; Okuda, N; Omae, T; Takishita, S, 2000) |
| "Both the lard and sucrose enrichment increased SBP and body weight compared with controls." | 3.70 | Dietary fat-induced increase in blood pressure and insulin resistance in rats. ( Hotta, N; Iguchi, A; Miura, H; Nakamura, J; Tamagawa, T; Tamaya, N; Uemura, K; Yoshioka, S, 2000) |
| "Troglitazone (T) and d-chiroinositol (DCI) have been reported to improve insulin resistance associated with obesity and NIDDM." | 3.70 | Pharmacological treatments for GH-induced insulin resistance. ( Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sugimoto, M; Takeda, N; Yasuda, K; Yoshino, K, 1999) |
| "Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects." | 3.69 | Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995) |
| "Troglitazone is a new orally active hypoglycemic agent that has been shown to reduce insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects." | 3.69 | Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1994) |
| "Troglitazone, a newly developed oral antidiabetic agent, improves hyperglycemia, and has been reported to improve insulin resistance and to decrease hepatic glucose production in diabetic animals." | 3.69 | Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. ( Higa, S; Ishikawa, K; Mimura, G; Murakami, K; Takasu, N; Yagi, N, 1995) |
| "We investigated whether troglitazone (CS-045, an insulin sensitizer) has an antihypertensive effect in fructose (FRU)-fed Wistar rats with insulin resistance and simultaneously compared its hypotensive efficacy with those of alacepril (ALA, an angiotensin converting enzyme inhibitor) and TCV-116 (an AT1a receptor antagonist)." | 3.69 | A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. ( Chen, S; Izumida, T; Katayama, S; Noguchi, Y; Tatebe, J, 1996) |
| "Troglitazone (TRG) is an orally active antidiabetic agent that increases insulin sensitivity in models of non-insulin-dependent diabetes mellitus (NIDDM), subsequently reducing hyperinsulinemia and hyperglycemia." | 3.69 | Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. ( Cornicelli, JA; Davis, JA; O'Rourke, CM; Saltiel, AR, 1997) |
| "Troglitazone is a newly developed antidiabetic drug that has been shown to improve insulin resistance and hyperinsulinemia both in diabetic animal models and in patients with non-insulin-dependent diabetes mellitus." | 3.69 | Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis. ( Arakawa, K; Saku, K; Zhang, B, 1997) |
| " Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]." | 3.69 | Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. ( Cavaghan, MK; Ehrmann, DA; Imperial, J; Polonsky, KS; Rosenfield, RL; Schneider, DJ; Sobel, BE, 1997) |
| "Metformin treatment had no significant impact on GSK-3 protein expression in either adipocytes or skeletal muscle." | 2.72 | Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. ( Baxi, S; Christiansen, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, S; Nikoulina, SE; Oh, DK, 2006) |
| " The objective of this study was to examine the impact of chronic use of an insulin sensitizer on glucose metabolism in normal glucose tolerant AA at risk for DM (previous gestational diabetes mellitus [GDM] or first-degree relative with DM)." | 2.71 | The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study. ( Gaillard, T; Habash, D; Osei, K; Rhinesmith, S; Schuster, D, 2003) |
| "A total of 34 subjects with type 2 diabetes (17 men and 17 women, aged 54+/-2 years and body mass index (BMI) 26." | 2.71 | Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. ( Ishibashi, S; Ishikawa, SE; Kusaka, I; Nagasaka, S; Nakamura, T; Yatagai, T; Yoshitaka, A, 2004) |
| "Troglitazone therapy was compared with other DPP interventions, considering both the short-term "in-trial" results and the longer-term results after troglitazone were discontinued." | 2.71 | Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. ( Barrett-Connor, E; Edelstein, SL; Ehrmann, DA; Fowler, SE; Hamman, RF; Kahn, SE; Knowler, WC; Nathan, DM; Walker, EA, 2005) |
| "Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women." | 2.70 | Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Hodis, HN; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Tan, S; Xiang, AH, 2002) |
| "Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes mellitus." | 2.69 | Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. ( Buchanan, TA; Burant, CF; Cline, G; Gumbiner, B; Hsueh, WA; Inzucchi, S; Kelley, D; Maggs, DG; Nolan, J; Olefsky, JM; Polonsky, KS; Shulman, GI; Silver, D; Valiquett, TR, 1998) |
| "Troglitazone treatment resulted in a decrease in fasting plasma glucose from 11." | 2.69 | Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. ( Kahn, SE; Porte, D; Prigeon, RL, 1998) |
| "Insulin resistance is associated with a decreased vasodilator response to insulin." | 2.69 | Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. ( Lutterman, JA; Ong, MK; Smits, P; Tack, CJ, 1998) |
| "The management of Type 2 diabetes mellitus with currently available oral agents may be complicated in the elderly by an increased frequency of side-effects." | 2.69 | Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. ( Barnett, AH; Kumar, S; Lettis, S; Prange, A; Schulze, J, 1998) |
| "Insulin resistance is associated with atherogenic lipoprotein phenotype, including small dense LDL particle, hypertriglycemia and low HDL cholesterol levels." | 2.69 | Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. ( Daida, H; Mokuno, H; Ohmura, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 1999) |
| "Treatment with troglitazone 400 mg q." | 2.69 | Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. ( Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R, 2000) |
| "Insulin resistance is a potential target for pharmacologic intervention in non-insulin-dependent diabetes." | 2.68 | Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. ( Anichini, R; Ferrannini, E; Foot, E; Gastaldelli, A; Pecori, N; Seghieri, G; Sironi, AM; Vichi, S, 1997) |
| " This article reviews the clinical data behind the use of metformin in combination with TZDs for the management of diabetes, its impact on vascular health, side effects and potential mechanisms of action for combined use." | 2.44 | Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. ( Elasy, T; Stafford, JM, 2007) |
| "Treatment with metformin was less effective than lifestyle modifications, resulting in an average reduction of risk for development of type 2 diabetes by 31% compared with placebo." | 2.42 | [Progress in the prevention of type 2 diabetes]. ( Schernthaner, G, 2003) |
| "Troglitazone was designed to combine tocopherol, anti-peroxidant, and thiazolidinedione." | 2.41 | [The development of thiazolidinedione drugs as anti-diabetic agents]. ( Kuzuya, T, 2000) |
| "Insulin resistance syndrome is the theory that glucose intolerance, hyperinsulinemia, increased very low density lipoprotein triglyceride level, decreased high density lipoprotein cholesterol level, and hypertension are proposed consequences of insulin resistance." | 2.41 | [Insulin sensitizer and hypertension]. ( Shimamoto, K, 2000) |
| "Insulin resistance is thought to lead to overproduction of very low-density lipoprotein (VLDL) cholesterol through the decreased peripheral lipoprotein lipase (LPL) activity, increased production of apolipoprotein B-100 and decreased clearance of remnant particles." | 2.41 | [Dyslipidemia in insulin resistance and its improvement by troglitazone]. ( Mabuchi, H; Yagi, K, 2000) |
| "Insulin resistance is known to unite several metabolic abnormalities." | 2.41 | Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. ( Daida, H; Sunayama, S; Watanabe, Y; Yamaguchi, H, 2000) |
| "Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world." | 2.41 | New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. ( Henry, RR; Mudaliar, S, 2001) |
| "Insulin resistance is a change in physiologic regulation such that a fixed dose of insulin causes less of an effect on glucose metabolism than occurs in normal individuals." | 2.41 | Insulin resistance and its treatment by thiazolidinediones. ( Banerji, MA; Lebovitz, HE, 2001) |
| "Moreover, hypertension was reported to be a possible cause of insulin resistance." | 2.40 | [Insulin, as a regulating factor of blood pressure]. ( Hamada, Y; Ikegami, H; Ogihara, T, 1997) |
| "Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes." | 2.40 | Troglitazone. Is it all over? ( Hoekstra, JB; Kuck, EM; Wagenaar, LJ, 1999) |
| "The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes." | 2.40 | [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. ( Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N, 1999) |
| "Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality." | 2.40 | New agents for Type 2 diabetes. ( Bailey, CJ; Nattrass, M, 1999) |
| "Troglitazone (TGZ) was used as an insulin sensitizer." | 1.39 | Role of insulin resistance in the pathogenesis and development of type 2 diabetes in WBN/Kob-Lepr(fa) rats. ( Asai, F; Kaji, N; Nagakubo, D; Ohno-Ichiki, K; Okuno, A; Shirai, M; Takahashi, A, 2013) |
| "There is evidence that one of the key type 2 diabetes (T2D) loci identified by GWAS exerts its influence early on in life through its impact on pediatric BMI." | 1.38 | Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23. ( Aziz, AR; Deliard, S; Grant, SF; Zhao, J, 2012) |
| "A total of 32 patients with type 2 diabetes were studied." | 1.33 | Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. ( Babaya, N; Fujisawa, T; Ikegami, H; Inoue, K; Itoi-Babaya, M; Kawabata, Y; Nishino, M; Nojima, K; Ogihara, T; Ono, M; Taniguchi, H, 2005) |
| "Insulin resistance is a common feature of both polycystic ovary syndrome (PCOS) and non-insulin-dependent diabetes mellitus (NIDDM); however, the persistent reproductive disturbances appear to be limited to the former, suggesting that insulin resistance in the ovary itself may confer this susceptibility." | 1.32 | Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. ( Erkkola, R; Liu, JX; Mäkinen, M; Pöllänen, P; Sallinen, K; Wu, XK; Zhou, SY, 2003) |
| "Troglitazone (TGZ) is an antidiabetic agent of the thiazolidinedione (TZD) class that potentiates insulin action." | 1.31 | Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats. ( Cho, KY; Kim, DK; Lee, MK; Min, KM; Park, GS; Park, SW; Song, MS, 2002) |
| "Troglitazone treatment restored those alterations in PTPase activity in the particulate fraction and the amounts of LAR, PTP1B and SH-PTP2 in both fractions of visceral and epididymal adipose tissues of OLETF rats." | 1.31 | Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats. ( Homma, H; Honda, T; Ide, H; Kawakami, Y; Ohno, K; Sakaue, S; Tagami, S; Yoshimura, H, 2002) |
| "Troglitazone treatment significantly increased pancreatic wet weight and protein, DNA, and enzyme contents compared with those in the control rats." | 1.31 | Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats. ( Akiyama, T; Fukumitsu, KI; Jia, DM; Otsuki, M; Tabaru, A, 2001) |
| "This finding suggests that primary treatment of insulin resistance could prevent the development of atherosclerosis by improving endothelial dysfunction." | 1.31 | Troglitazone improves endothelial dysfunction in patients with insulin resistance. ( Daida, H; Hoshi, S; Iwama, Y; Mokuno, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 2000) |
| "Troglitazone, which has no effect on PDE3B in liver, increased the expression of this gene in adipocytes." | 1.31 | Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse. ( Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Sugita, A; Tang, Y, 2001) |
| "Troglitazone may be useful in the treatment of insulin resistance as well as of hypertensive vascular diseases." | 1.31 | Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. ( Chikara, S; Fukuda, N; Hu, WY; Kanmatsuse, K; Kishioka, H; Nakayama, M; Teng, J, 2002) |
| "Insulin resistance in Werner's syndrome (WS) is probably due to defective signaling distal to the insulin receptor." | 1.30 | Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. ( Akazawa, S; Chikuba, N; Ishibashi, M; Izumino, K; Matsumoto, K; Nagataki, S; Sakamaki, H; Takino, H; Tokuyama, K; Yamaguchi, Y; Yamasaki, H, 1997) |
| "Troglitazone treatment completely prevented the TNF-alpha-induced decline in submaximal GDR (133 +/- 16 vs." | 1.30 | TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. ( Cohen, A; Higo, K; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1997) |
| "Troglitazone treatment decreased skeletal muscle, but not hepatic triglyceride and increased hepatic and muscle glycogen content in wild-type mice." | 1.30 | Troglitazone action is independent of adipose tissue. ( Burant, CF; Davidson, NO; Graves, RA; Hirano, K; Lohmiller, J; Lukens, J; Ross, S; Sreenan, S; Tai, TA, 1997) |
| "Troglitazone treatment largely prevented the hyperglycemia-induced decline in submaximal (116 +/- 7 micromol x kg(-1) x min[-1]) and maximal GDR (209 +/- 9 micromol x kg(-1) x min(-1); P < 0." | 1.30 | Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. ( Higo, K; Lee, MK; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1998) |
| "Troglitazone was given at 100 mg/kg/d orally for 5 days before and 2 days during rhGH." | 1.30 | Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats. ( Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1998) |
| "Since WHHL rabbits show hyperinsulinemia and insulin resistance, we administered troglitazone (100 mg/kg), an insulin action enhancer, pravastatin sodium (50 mg/kg), an HMG CoA reductase inhibitor, and a combination of both drugs to 2-month-old WHHL rabbits for 32 weeks." | 1.30 | Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. ( Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T, 1999) |
| "Troglitazone appears to increase both glycogen and TG turnover in skeletal muscle." | 1.30 | Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. ( Burant, CF; Cockburn, B; Fuller, T; Keck, S; Sreenan, S, 1999) |
| "Troglitazone was obtained in 5 steps from 4-bromo-1,1-dimethoxy-3-methylbut-2-ene with an overall yield of 7." | 1.30 | A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance. ( Cossy, J; Desmurs, JR; Kahn, PH; Menciu, C; Rakotoarisoa, H, 1999) |
| "Werner's syndrome is a rare inheritated disorder characterized by accelerated aging and is often accompanied by diabetes mellitus or impaired glucose tolerance." | 1.29 | Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. ( Akazawa, S; Kawasaki, E; Matsumoto, K; Okuno, S; Takao, Y; Takino, H; Uotani, S; Yamaguchi, Y; Yamasaki, H; Yano, M, 1994) |
| "Obesity is characterized by hyperinsulinemia, which reflects peripheral insulin resistance." | 1.29 | Antihypertensive effects of CS-045 treatment in obese Zucker rats. ( Fujiwara, T; Horikoshi, H; Ikeda, K; Koike, H; Nishino, H; Okuno, A; Shiraki, T; Wada, M; Yoshioka, S, 1993) |
| " Furthermore, 2-deoxyglucose uptake in CS-045-treated adipocytes was increased and the insulin dose-response curve was shifted to the left." | 1.27 | Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. ( Fujiwara, T; Horikoshi, H; Ushiyama, I; Yoshioka, S; Yoshioka, T, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.45) | 18.7374 |
| 1990's | 93 (42.27) | 18.2507 |
| 2000's | 117 (53.18) | 29.6817 |
| 2010's | 9 (4.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, J | 1 |
| Bailey, P | 1 |
| Biswas, C | 1 |
| Cullinan, CA | 1 |
| Doebber, TW | 1 |
| Hayes, NS | 1 |
| Saperstein, R | 1 |
| Smith, RG | 1 |
| Leibowitz, MD | 1 |
| Porcelli, L | 1 |
| Gilardi, F | 1 |
| Laghezza, A | 1 |
| Piemontese, L | 1 |
| Mitro, N | 1 |
| Azzariti, A | 1 |
| Altieri, F | 1 |
| Cervoni, L | 1 |
| Fracchiolla, G | 1 |
| Giudici, M | 1 |
| Guerrini, U | 1 |
| Lavecchia, A | 1 |
| Montanari, R | 1 |
| Di Giovanni, C | 1 |
| Paradiso, A | 1 |
| Pochetti, G | 1 |
| Simone, GM | 1 |
| Tortorella, P | 1 |
| Crestani, M | 1 |
| Loiodice, F | 1 |
| Yu, J | 1 |
| Ahn, S | 2 |
| Kim, HJ | 1 |
| Lee, M | 1 |
| Kim, J | 1 |
| Jin, SH | 1 |
| Lee, E | 1 |
| Kim, G | 1 |
| Cheong, JH | 1 |
| Jacobson, KA | 1 |
| Jeong, LS | 1 |
| Noh, M | 1 |
| Tanis, SP | 1 |
| Colca, JR | 1 |
| Parker, TT | 1 |
| Artman, GD | 1 |
| Larsen, SD | 1 |
| McDonald, WG | 1 |
| Gadwood, RC | 1 |
| Kletzien, RF | 1 |
| Zeller, JB | 1 |
| Lee, PH | 1 |
| Adams, WJ | 1 |
| Banerjee, S | 1 |
| Talukdar, I | 1 |
| Banerjee, A | 1 |
| Gupta, A | 1 |
| Balaji, A | 1 |
| Aduri, R | 1 |
| Tsujino, Y | 1 |
| Okuno, A | 3 |
| Kaji, N | 1 |
| Takahashi, A | 1 |
| Nagakubo, D | 1 |
| Ohno-Ichiki, K | 1 |
| Shirai, M | 1 |
| Asai, F | 1 |
| He, J | 1 |
| Xu, C | 1 |
| Kuang, J | 1 |
| Liu, Q | 1 |
| Jiang, H | 1 |
| Mo, L | 1 |
| Geng, B | 1 |
| Xu, G | 2 |
| Qu, J | 1 |
| Wang, Y | 1 |
| Wu, X | 1 |
| Gao, L | 1 |
| Hou, L | 1 |
| Erkkola, R | 2 |
| Tsuchiya, Y | 1 |
| Hatakeyama, H | 1 |
| Emoto, N | 1 |
| Wagatsuma, F | 1 |
| Matsushita, S | 1 |
| Kanzaki, M | 1 |
| Zhao, J | 1 |
| Deliard, S | 1 |
| Aziz, AR | 1 |
| Grant, SF | 1 |
| Min, KM | 1 |
| Park, SW | 1 |
| Cho, KY | 1 |
| Song, MS | 1 |
| Kim, DK | 1 |
| Park, GS | 1 |
| Lee, MK | 4 |
| Tsunoda, S | 1 |
| Kamide, K | 1 |
| Minami, J | 2 |
| Kawano, Y | 2 |
| Buchanan, TA | 4 |
| Xiang, AH | 3 |
| Peters, RK | 3 |
| Kjos, SL | 3 |
| Marroquin, A | 3 |
| Goico, J | 3 |
| Ochoa, C | 3 |
| Tan, S | 3 |
| Berkowitz, K | 1 |
| Hodis, HN | 3 |
| Azen, SP | 3 |
| Kono, S | 1 |
| Willi, SM | 1 |
| Kennedy, A | 1 |
| Wallace, P | 1 |
| Ganaway, E | 1 |
| Rogers, NL | 1 |
| Garvey, WT | 2 |
| Wasada, T | 2 |
| Iwatani, M | 2 |
| Tagami, S | 1 |
| Honda, T | 1 |
| Yoshimura, H | 1 |
| Homma, H | 1 |
| Ohno, K | 1 |
| Ide, H | 1 |
| Sakaue, S | 1 |
| Kawakami, Y | 1 |
| Raji, A | 1 |
| Plutzky, J | 2 |
| Yamanouchi, T | 3 |
| Ohmura, E | 1 |
| Hosaka, D | 1 |
| Imai, Y | 1 |
| Kawazu, S | 1 |
| Kitaoka, H | 2 |
| Kalderon, B | 1 |
| Mayorek, N | 1 |
| Ben-Yaacov, L | 1 |
| Bar-Tana, J | 1 |
| Miles, PD | 5 |
| Barak, Y | 1 |
| Evans, RM | 1 |
| Olefsky, JM | 8 |
| Paradisi, G | 1 |
| Steinberg, HO | 1 |
| Shepard, MK | 1 |
| Hook, G | 1 |
| Baron, AD | 1 |
| Sekino, N | 1 |
| Kashiwabara, A | 1 |
| Inoue, T | 1 |
| Kawasaki, T | 1 |
| Ogata, N | 1 |
| Sawashige, K | 1 |
| Gras, F | 2 |
| Brunmair, B | 2 |
| Roden, M | 2 |
| Waldhäusl, W | 3 |
| Fürnsinn, C | 3 |
| Wilmsen, HM | 1 |
| Ciaraldi, TP | 2 |
| Carter, L | 1 |
| Reehman, N | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 5 |
| Stakos, DA | 1 |
| Schuster, DP | 1 |
| Sparks, EA | 1 |
| Wooley, CF | 1 |
| Osei, K | 2 |
| Boudoulas, H | 1 |
| Azziz, R | 2 |
| Ehrmann, DA | 4 |
| Legro, RS | 2 |
| Fereshetian, AG | 2 |
| O'Keefe, M | 2 |
| Ghazzi, MN | 2 |
| Pugeat, M | 1 |
| Baillargeon, JP | 1 |
| Iuorno, MJ | 2 |
| Nestler, JE | 3 |
| Schuster, D | 1 |
| Gaillard, T | 1 |
| Rhinesmith, S | 1 |
| Habash, D | 1 |
| Wu, XK | 1 |
| Zhou, SY | 1 |
| Liu, JX | 1 |
| Pöllänen, P | 1 |
| Sallinen, K | 1 |
| Mäkinen, M | 1 |
| Ehrmann, D | 1 |
| Yatagai, T | 1 |
| Nakamura, T | 3 |
| Nagasaka, S | 2 |
| Kusaka, I | 1 |
| Ishikawa, SE | 1 |
| Yoshitaka, A | 1 |
| Ishibashi, S | 1 |
| Gilling, L | 1 |
| Suwattee, P | 1 |
| DeSouza, C | 2 |
| Asnani, S | 1 |
| Fonseca, V | 2 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Schernthaner, G | 1 |
| Zirlik, A | 1 |
| Leugers, A | 1 |
| Lohrmann, J | 1 |
| Ernst, S | 1 |
| Sobel, BE | 4 |
| Bode, C | 1 |
| Nordt, TK | 1 |
| Grassi, G | 1 |
| Watanabe, K | 2 |
| Komatsu, J | 1 |
| Kurata, M | 1 |
| Inaba, S | 1 |
| Ikeda, S | 1 |
| Sueda, S | 1 |
| Suzuki, J | 2 |
| Kohara, K | 1 |
| Hamada, M | 1 |
| Wang, C | 1 |
| Liu, CR | 1 |
| Liu, CH | 1 |
| Reamy, BV | 1 |
| Montanaro, MA | 1 |
| Lombardo, YB | 1 |
| González, MS | 1 |
| Bernasconi, AM | 1 |
| Chicco, A | 1 |
| Rimoldi, OJ | 1 |
| Basabe, JC | 1 |
| Brenner, RR | 1 |
| Knowler, WC | 1 |
| Hamman, RF | 1 |
| Edelstein, SL | 1 |
| Barrett-Connor, E | 1 |
| Walker, EA | 1 |
| Fowler, SE | 1 |
| Nathan, DM | 1 |
| Kahn, SE | 2 |
| Ono, M | 1 |
| Ikegami, H | 3 |
| Fujisawa, T | 1 |
| Nojima, K | 1 |
| Kawabata, Y | 1 |
| Nishino, M | 1 |
| Taniguchi, H | 1 |
| Itoi-Babaya, M | 1 |
| Babaya, N | 1 |
| Inoue, K | 1 |
| Ogihara, T | 3 |
| Moreno Sánchez, D | 1 |
| Matsumoto, H | 1 |
| Nakao, T | 1 |
| Okada, T | 1 |
| Nagaoka, Y | 1 |
| Iwasawa, H | 1 |
| Tomaru, R | 1 |
| Wada, T | 1 |
| Matsushita, M | 1 |
| Tamura, K | 1 |
| Osada, S | 1 |
| Kogo, H | 1 |
| Grant, RW | 1 |
| Meigs, JB | 1 |
| Oh, DK | 1 |
| Christiansen, L | 1 |
| Nikoulina, SE | 1 |
| Kong, AP | 1 |
| Baxi, S | 1 |
| Mudaliar, S | 2 |
| Kautzky-Willer, A | 1 |
| Tura, A | 1 |
| Winzer, C | 1 |
| Wagner, OF | 1 |
| Ludvik, B | 2 |
| Hanusch-Enserer, U | 1 |
| Prager, R | 1 |
| Pacini, G | 1 |
| Zhang, J | 1 |
| Wright, W | 1 |
| Bernlohr, DA | 1 |
| Cushman, SW | 1 |
| Chen, X | 1 |
| Maraldi, NM | 1 |
| Capanni, C | 1 |
| Mattioli, E | 1 |
| Columbaro, M | 1 |
| Squarzoni, S | 1 |
| Parnaik, WK | 1 |
| Wehnert, M | 1 |
| Lattanzi, G | 1 |
| Zhou, L | 1 |
| Sell, H | 1 |
| Eckardt, K | 1 |
| Yang, Z | 1 |
| Eckel, J | 1 |
| Stafford, JM | 1 |
| Elasy, T | 1 |
| Khashab, M | 1 |
| Chalasani, N | 1 |
| Ozel Demiralp, D | 1 |
| Aktas, H | 1 |
| Akar, N | 1 |
| Khoursheed, M | 2 |
| Gao, KM | 2 |
| Moossa, AR | 2 |
| Kellerer, M | 1 |
| Kroder, G | 1 |
| Tippmer, S | 1 |
| Berti, L | 1 |
| Kiehn, R | 1 |
| Mosthaf, L | 1 |
| Häring, H | 1 |
| Reusch, JE | 1 |
| Rakugi, H | 1 |
| Mikami, H | 1 |
| Masuo, K | 1 |
| Tominaga, M | 2 |
| Igarashi, M | 1 |
| Daimon, M | 2 |
| Eguchi, H | 1 |
| Matsumoto, M | 1 |
| Sekikawa, A | 1 |
| Yamatani, K | 1 |
| Sasaki, H | 2 |
| Nolan, JJ | 1 |
| Beerdsen, P | 1 |
| Joyce, M | 1 |
| Olefsky, J | 2 |
| Keen, H | 1 |
| Takino, H | 2 |
| Okuno, S | 1 |
| Uotani, S | 1 |
| Yano, M | 1 |
| Matsumoto, K | 2 |
| Kawasaki, E | 1 |
| Takao, Y | 1 |
| Yamasaki, H | 2 |
| Yamaguchi, Y | 2 |
| Akazawa, S | 2 |
| Katayama, S | 4 |
| Abe, M | 1 |
| Kashiwabara, H | 1 |
| Kosegawa, I | 2 |
| Ishii, J | 2 |
| Yoshioka, S | 3 |
| Nishino, H | 1 |
| Shiraki, T | 1 |
| Ikeda, K | 1 |
| Koike, H | 1 |
| Wada, M | 1 |
| Fujiwara, T | 4 |
| Horikoshi, H | 6 |
| Kawaguchi, M | 1 |
| Tanigawa, K | 1 |
| Kato, Y | 1 |
| Umeda, F | 1 |
| Yagi, N | 1 |
| Takasu, N | 1 |
| Higa, S | 1 |
| Ishikawa, K | 1 |
| Murakami, K | 1 |
| Mimura, G | 1 |
| Dunaif, A | 2 |
| Scott, D | 1 |
| Finegood, D | 1 |
| Quintana, B | 1 |
| Whitcomb, R | 1 |
| Kawamori, R | 1 |
| Yoshii, H | 1 |
| Chen, S | 2 |
| Noguchi, Y | 1 |
| Izumida, T | 1 |
| Tatebe, J | 1 |
| Petrie, J | 1 |
| Small, M | 1 |
| Connell, J | 1 |
| O'Rourke, CM | 1 |
| Davis, JA | 1 |
| Saltiel, AR | 1 |
| Cornicelli, JA | 1 |
| Zhang, B | 2 |
| Saku, K | 2 |
| Arakawa, K | 2 |
| Vidt, DG | 1 |
| Speerhas, RA | 1 |
| Reddy, SS | 1 |
| Mantzoros, CS | 1 |
| Flier, JS | 1 |
| Hirose, T | 1 |
| Kurebayashi, S | 1 |
| Schneider, DJ | 1 |
| Cavaghan, MK | 1 |
| Imperial, J | 1 |
| Rosenfield, RL | 1 |
| Polonsky, KS | 2 |
| Iwamoto, Y | 4 |
| Ishikawa, S | 1 |
| Kuzuya, T | 2 |
| Saito, T | 2 |
| Izumino, K | 1 |
| Sakamaki, H | 1 |
| Ishibashi, M | 1 |
| Chikuba, N | 1 |
| Tokuyama, K | 1 |
| Nagataki, S | 1 |
| Hamada, Y | 1 |
| Sironi, AM | 1 |
| Vichi, S | 1 |
| Gastaldelli, A | 1 |
| Pecori, N | 1 |
| Anichini, R | 1 |
| Foot, E | 1 |
| Seghieri, G | 1 |
| Ferrannini, E | 1 |
| Ohta, T | 1 |
| Romeo, OM | 2 |
| Higo, K | 2 |
| Cohen, A | 1 |
| Rafaat, K | 2 |
| Burant, CF | 3 |
| Sreenan, S | 2 |
| Hirano, K | 1 |
| Tai, TA | 1 |
| Lohmiller, J | 1 |
| Lukens, J | 1 |
| Davidson, NO | 1 |
| Ross, S | 1 |
| Graves, RA | 1 |
| Camirand, A | 1 |
| Marie, V | 1 |
| Rabelo, R | 1 |
| Silva, JE | 1 |
| Sakamoto, N | 1 |
| Uno, T | 1 |
| Inoue, I | 1 |
| Ciaraldi, T | 1 |
| Maggs, DG | 1 |
| Cline, G | 1 |
| Gumbiner, B | 1 |
| Hsueh, WA | 1 |
| Inzucchi, S | 1 |
| Kelley, D | 1 |
| Nolan, J | 1 |
| Silver, D | 1 |
| Valiquett, TR | 1 |
| Shulman, GI | 1 |
| Okumura, S | 4 |
| Takeda, N | 4 |
| Takami, K | 3 |
| Yoshino, K | 4 |
| Hattori, J | 4 |
| Nakashima, K | 4 |
| Sugimoto, M | 4 |
| Ishimori, M | 3 |
| Takami, R | 3 |
| Yasuda, K | 4 |
| Tamemoto, H | 1 |
| Tobe, K | 1 |
| Ueki, K | 1 |
| Mori, Y | 1 |
| Iwamoto, K | 1 |
| Umesono, K | 1 |
| Akanuma, Y | 1 |
| Yazaki, Y | 1 |
| Kadowaki, T | 2 |
| Prigeon, RL | 1 |
| Porte, D | 1 |
| Johnson, MD | 1 |
| Campbell, LK | 1 |
| Campbell, RK | 1 |
| Shinohara, E | 2 |
| Kihara, S | 2 |
| Ouchi, N | 2 |
| Funahashi, T | 2 |
| Yamashita, S | 2 |
| Kameda-Takemura, K | 1 |
| Matsuzawa, Y | 2 |
| Tamura, R | 1 |
| Bornkessel, B | 1 |
| Tack, CJ | 5 |
| Smits, P | 5 |
| Demacker, PN | 2 |
| Stalenhoef, AF | 2 |
| Ong, MK | 1 |
| Lutterman, JA | 1 |
| Sattar, N | 1 |
| Hopkinson, ZE | 1 |
| Greer, IA | 1 |
| Sasaki, A | 2 |
| Hirano, T | 1 |
| Yoshino, G | 1 |
| Kazumi, T | 1 |
| Riddle, MC | 1 |
| Shimizu, H | 1 |
| Tsuchiya, T | 1 |
| Sato, N | 1 |
| Shimomura, Y | 1 |
| Kobayashi, I | 1 |
| Mori, M | 1 |
| Kumar, S | 1 |
| Prange, A | 1 |
| Schulze, J | 1 |
| Lettis, S | 1 |
| Barnett, AH | 1 |
| Ranganathan, S | 1 |
| Kern, PA | 1 |
| Komers, R | 1 |
| Vrána, A | 1 |
| Mokuda, O | 1 |
| Sakamoto, Y | 1 |
| Sonnenberg, GE | 1 |
| Kotchen, TA | 1 |
| Yamakita, T | 1 |
| Ishii, T | 1 |
| Mori, T | 1 |
| Yoshioka, K | 1 |
| Sato, T | 2 |
| Tanaka, S | 1 |
| Kurimasa, H | 1 |
| Fujita, K | 1 |
| Fujii, S | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Hasegawa, I | 1 |
| Murakawa, H | 1 |
| Suzuki, M | 1 |
| Yamamoto, Y | 1 |
| Kurabayashi, T | 1 |
| Tanaka, K | 1 |
| Shiomi, M | 1 |
| Ito, T | 2 |
| Tsukada, T | 1 |
| Tsujita, Y | 1 |
| McCarty, MF | 1 |
| Cooksey, RC | 1 |
| Hebert, LF | 1 |
| Zhu, JH | 1 |
| Wofford, P | 1 |
| McClain, DA | 1 |
| Kashiwagi, K | 1 |
| Nagafuchi, S | 1 |
| Sekiguchi, N | 1 |
| Yamagata, A | 1 |
| Iwata, I | 1 |
| Furuya, H | 1 |
| Kato, M | 1 |
| Niho, Y | 1 |
| Awata, T | 1 |
| Negishi, K | 1 |
| Elkind-Hirsch, KE | 1 |
| McWilliams, RB | 1 |
| Keck, S | 1 |
| Fuller, T | 1 |
| Cockburn, B | 1 |
| Blonde, L | 1 |
| Sandberg, MI | 1 |
| Guthrie, RD | 1 |
| Kwon, G | 1 |
| Marshall, CA | 1 |
| McDaniel, ML | 1 |
| Murakami, T | 1 |
| Mizuno, S | 1 |
| Ohsato, K | 1 |
| Moriuchi, I | 1 |
| Arai, Y | 1 |
| Nio, Y | 1 |
| Kaku, B | 1 |
| Takahashi, Y | 1 |
| Ohnaka, M | 1 |
| Aoki, K | 2 |
| Satoh, S | 2 |
| Mukasa, K | 2 |
| Kaneshiro, M | 1 |
| Kawasaki, S | 1 |
| Okamura, A | 2 |
| Sekihara, H | 2 |
| Wagenaar, LJ | 1 |
| Kuck, EM | 1 |
| Hoekstra, JB | 1 |
| Brogard, JM | 1 |
| Neyrolles, N | 1 |
| Andres, E | 1 |
| Blicklé, JF | 1 |
| Scheen, AJ | 2 |
| Lefèbvre, PJ | 2 |
| Sunayama, S | 3 |
| Watanabe, Y | 3 |
| Ohmura, H | 1 |
| Sawano, M | 2 |
| Shimada, K | 2 |
| Mokuno, H | 2 |
| Daida, H | 3 |
| Yamaguchi, H | 3 |
| Ginsberg, H | 1 |
| Zimmet, P | 1 |
| Collier, G | 1 |
| Kawachi, S | 1 |
| Cossy, J | 1 |
| Menciu, C | 1 |
| Rakotoarisoa, H | 1 |
| Kahn, PH | 1 |
| Desmurs, JR | 1 |
| Van Den Bergh, AJ | 1 |
| Van Den Boogert, HJ | 1 |
| Vervoort, G | 1 |
| Heerschap, A | 1 |
| Shimizu, N | 1 |
| Shimamoto, K | 1 |
| Yagi, K | 1 |
| Mabuchi, H | 1 |
| Kamatani, N | 1 |
| Yamada, K | 1 |
| Kuzuya, H | 1 |
| Nakano, T | 1 |
| Isshiki, K | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Kikkawa, R | 1 |
| Sanaka, M | 1 |
| Matsui, J | 1 |
| Nakamura, J | 2 |
| Ogawa, Y | 1 |
| Suda, T | 1 |
| Zhu, P | 1 |
| Lu, L | 1 |
| Xu, Y | 1 |
| Schwartz, GG | 1 |
| Paquot, N | 1 |
| Letiexhe, MR | 1 |
| Nattrass, M | 1 |
| Bailey, CJ | 2 |
| Yachi, M | 1 |
| Anil Kumar, KL | 1 |
| Marita, AR | 1 |
| Kimura, M | 1 |
| Manaka, H | 1 |
| Kato, T | 1 |
| Walli, R | 1 |
| Michl, GM | 1 |
| Mühlbayer, D | 1 |
| Brinkmann, L | 1 |
| Goebel, FD | 1 |
| Diamanti-Kandarakis, E | 1 |
| Zapanti, E | 1 |
| Kruszynska, YT | 1 |
| Yu, JG | 1 |
| Westerbacka, J | 1 |
| Yki-Järvinen, H | 1 |
| Krentz, AJ | 1 |
| Melander, A | 1 |
| Takahashi, S | 1 |
| Oida, K | 1 |
| Miyamori, I | 1 |
| Arioglu, E | 1 |
| Duncan-Morin, J | 1 |
| Sebring, N | 1 |
| Rother, KI | 1 |
| Gottlieb, N | 1 |
| Lieberman, J | 1 |
| Herion, D | 1 |
| Kleiner, DE | 1 |
| Reynolds, J | 1 |
| Premkumar, A | 1 |
| Sumner, AE | 1 |
| Hoofnagle, J | 1 |
| Reitman, ML | 1 |
| Taylor, SI | 1 |
| Ganda, OP | 1 |
| Naruse, M | 1 |
| Yoshimoto, T | 1 |
| Tanabe, A | 1 |
| Takagi, S | 1 |
| Tago, K | 1 |
| Takano, K | 1 |
| Russell, JC | 1 |
| Ravel, D | 1 |
| Pégorier, JP | 1 |
| Delrat, P | 1 |
| Jochemsen, R | 1 |
| O'Brien, SF | 1 |
| Kelly, SE | 1 |
| Davidge, ST | 1 |
| Brindley, DN | 1 |
| Filz, HP | 1 |
| Okuda, N | 1 |
| Takishita, S | 1 |
| Omae, T | 1 |
| Kawabe, J | 1 |
| Aizawa, Y | 1 |
| Takehara, N | 1 |
| Hasebe, N | 1 |
| Kikuchi, K | 1 |
| Fujiwara, K | 1 |
| Hayashi, K | 1 |
| Ozawa, Y | 1 |
| Tokuyama, H | 1 |
| Nakamura, A | 1 |
| Saruta, T | 1 |
| Oberkofler, H | 1 |
| Neschen, S | 2 |
| Esterbauer, H | 1 |
| Patsch, W | 1 |
| Uemura, K | 1 |
| Tamaya, N | 1 |
| Tamagawa, T | 1 |
| Miura, H | 1 |
| Iguchi, A | 1 |
| Hotta, N | 1 |
| Kausch, C | 1 |
| Krützfeldt, J | 1 |
| Witke, A | 1 |
| Rettig, A | 1 |
| Bachmann, O | 1 |
| Rett, K | 1 |
| Matthaei, S | 1 |
| Machicao, F | 1 |
| Häring, HU | 1 |
| Stumvoll, M | 1 |
| Katsuki, A | 1 |
| Sumida, Y | 1 |
| Murata, K | 1 |
| Furuta, M | 1 |
| Araki-Sasaki, R | 1 |
| Tsuchihashi, K | 1 |
| Hori, Y | 1 |
| Yano, Y | 1 |
| Gabazza, EC | 1 |
| Adachi, Y | 1 |
| Kikuchi, T | 1 |
| Ito, S | 1 |
| Nakajima, A | 1 |
| Sanyal, AJ | 1 |
| Lebovitz, HE | 1 |
| Banerji, MA | 1 |
| Yoshida, K | 1 |
| Kohzuki, M | 1 |
| Xu, HL | 1 |
| Wu, XM | 1 |
| Kamimoto, M | 1 |
| Jia, DM | 2 |
| Fukumitsu, KI | 1 |
| Tabaru, A | 1 |
| Akiyama, T | 1 |
| Otsuki, M | 2 |
| Morita, H | 1 |
| Oki, Y | 1 |
| Ohishi, H | 1 |
| Suzuki, S | 1 |
| Nakamura, H | 1 |
| Ma, LJ | 1 |
| Marcantoni, C | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Fogo, AB | 1 |
| Malacara, JM | 1 |
| Fajardo, ME | 1 |
| Nava, LE | 1 |
| Harano, Y | 1 |
| Chen, CC | 1 |
| Wang, HJ | 1 |
| Shih, HC | 1 |
| Sheen, LY | 1 |
| Chang, CT | 1 |
| Chen, RH | 1 |
| Wang, TY | 1 |
| Sekiya, M | 1 |
| Funada, J | 1 |
| Otani, T | 1 |
| Akutsu, H | 1 |
| Eto, K | 1 |
| Ohya, Y | 1 |
| Nakamura, Y | 1 |
| Abe, I | 1 |
| Fujishima, M | 1 |
| Yokoyama, I | 1 |
| Yonekura, K | 1 |
| Moritan, T | 1 |
| Tateno, M | 1 |
| Momose, T | 1 |
| Ohtomo, K | 1 |
| Inoue, Y | 1 |
| Nagai, R | 1 |
| Kitakoshi, K | 1 |
| Oshida, Y | 1 |
| Nakai, N | 1 |
| Han, YQ | 1 |
| Sato, Y | 1 |
| Hoshi, S | 1 |
| Iwama, Y | 1 |
| Maruyama, S | 1 |
| Yanagisawa, K | 1 |
| Kanamuro, R | 1 |
| Teno, S | 1 |
| Chvojková, S | 1 |
| Kazdová, L | 1 |
| Divisová, J | 1 |
| Solomon, SS | 1 |
| Usdan, LS | 1 |
| Palazzolo, MR | 1 |
| Jazet, IM | 1 |
| Meinders, AE | 1 |
| Wagner, L | 1 |
| Hevener, AL | 1 |
| Reichart, D | 1 |
| Janez, A | 1 |
| Tang, Y | 1 |
| Osawa, H | 1 |
| Onuma, H | 1 |
| Nishimiya, T | 1 |
| Ochi, M | 1 |
| Sugita, A | 1 |
| Makino, H | 1 |
| Gómez-Pérez, FJ | 1 |
| Aguilar-Salinas, CA | 1 |
| Vázquez-Chávez, C | 1 |
| Fanghänel-Salmón, G | 1 |
| Gallegos-Martínez, J | 1 |
| Gómez-Diaz, RA | 1 |
| Salinas-Orozco, S | 1 |
| Chavira-López, IJ | 1 |
| Sánchez-Reyes, L | 1 |
| Torres-Acosta, EM | 1 |
| Tamez, R | 1 |
| López, A | 1 |
| Guillén, LE | 1 |
| Cesarman, G | 1 |
| Montague, CT | 1 |
| Mei, J | 1 |
| Holst, LS | 1 |
| Landström, TR | 1 |
| Holm, C | 1 |
| Brindley, D | 1 |
| Manganiello, V | 1 |
| Degerman, E | 1 |
| Laboureau-Soares Barbosa, S | 1 |
| Rodien, P | 1 |
| Rohmer, V | 1 |
| Keebler, M | 1 |
| Dicker-Brown, A | 1 |
| Poirier, LA | 1 |
| Murthy, SN | 1 |
| McNamara, DB | 1 |
| Fukuda, N | 1 |
| Hu, WY | 1 |
| Teng, J | 1 |
| Chikara, S | 1 |
| Nakayama, M | 1 |
| Kishioka, H | 1 |
| Kanmatsuse, K | 1 |
| Yoshioka, T | 1 |
| Ushiyama, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272] | 128 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
| The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918] | 60 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471] | 36 participants (Anticipated) | Observational | 2012-12-06 | Active, not recruiting | |||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910] | Phase 4 | 41 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up) | ||
| Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring[NCT00290394] | Phase 4 | 25 participants | Interventional | 2004-03-31 | Completed | ||
| Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes[NCT00194896] | 64 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| [NCT01626443] | Phase 4 | 46 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Efficacy of Leptin Replacement in Treatment of Lipodystrophy[NCT00005905] | Phase 2 | 20 participants | Interventional | 2000-06-30 | Completed | ||
| Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy[NCT00025883] | Phase 2 | 103 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome[NCT02633488] | 19 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Effects of Rosiglitazone on Cognition in Patients With MCI[NCT00242593] | Phase 2 | 120 participants (Anticipated) | Interventional | 2006-06-30 | Active, not recruiting | ||
| Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes[NCT01156597] | Phase 3 | 30 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | 7.4 |
| Fenofibrate + Placebo | -2.2 |
| Rosiglitazone +Fenofibrate | 20 |
| Placebo Therapy Daily | 7.6 |
The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone and Placebo | 1.9 |
| Fenofibrate + Placebo | 14.5 |
| Rosiglitazone +Fenofibrate | 5.8 |
| Placebo Therapy Daily | 1.7 |
The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | -0.5 |
| Fenofibrate + Placebo | 2.6 |
| Rosiglitazone + Fenofibrate | 37.3 |
| Placebo Therapy Daily | 13.7 |
The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| AST 1 (aspartate aminotransferase [10-35 U/L]) | AST 12 (aspartate aminotransferase [15-37 U/L]) | ALT 1 (alanine aminotransferase [6-60 U/L]) | ALT 12 (alanine aminotransferase [6-60 U/L]) | |
| Fenofibrate + Placebo | 25.25 | 26.50 | 25.88 | 26.38 |
| Placebo Therapy Daily | 19.88 | 17.88 | 20.88 | 14.88 |
| Rosiglitazone + Placebo | 24.00 | 30.29 | 28.14 | 27.43 |
| Rosiglitazone +Fenofibrate | 24.30 | 19.70 | 24.10 | 21.10 |
Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % Change (Median) | ||
|---|---|---|---|
| Apo AI | Apo AII | Apo CIII | |
| Fenofibrate + Placebo | 13 | 3.4 | -4.35 |
| Placebo Therapy Daily | 5 | -3.5 | -2.3 |
| Rosiglitazone + Placebo | -1.00 | 10.25 | 0.30 |
| Rosiglitazone +Fenofibrate | 1 | 7.2 | -5.3 |
Number of participants positive for T cell reactivity to islet proteins at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Rosiglitazone Autoantibody Positive | 1 |
| Rosiglitazone Autoantibody Negative | 2 |
| Glyburide Autoantibody Positive | 2 |
| Glyburide Autoantibody Negative | 3 |
Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | ng per ml (Mean) | |
|---|---|---|
| Fasting C-peptide | Glucagon Stimulated C-peptide | |
| Glyburide Autoantibody Negative | 0.3 | 0.3 |
| Glyburide Autoantibody Positive | 0.1 | 3.1 |
| Rosiglitazone Autoantibody Negative | -1.4 | -2.8 |
| Rosiglitazone Autoantibody Positive | -0.4 | -0.6 |
Percentage of glycosylated hemoglobin at Baseline, 6 months, and 12 months on treatment with metreleptin (NCT00025883)
Timeframe: Baseline, 6 months, 12 months
| Intervention | percentage of glycated hemoglobin (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Generalized Lipodystrophy (GLD) | 8.4 | 6.6 | 6.4 |
| Partial Lipodystrophy (PLD) | 8.1 | 7.2 | 7.3 |
(NCT00025883)
Timeframe: Baseline, 6 months, 12 months
| Intervention | mg/dL (Geometric Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Generalized Lipodystrophy (GLD) | 467 | 198 | 180 |
| Partial Lipodystrophy (PLD) | 483 | 339 | 326 |
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature (NCT02633488)
Timeframe: before and after 12 weeks on placebo or metformin
| Intervention | percentage of artery dilation (Mean) |
|---|---|
| Pre and Post Placebo 12 Weeks | 6.1 |
| Pre and Post Metformin 12 Weeks | 6.2 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
The ability of serum HDL to remove cholesterol from cultured cells will be assessed as an in vitro method to evaluate a functional changes in HDL mediated by changes due to pioglitazone treatment. Cells were incubated with 2% serum from each study subject diluted in culture medium and incubations were performed for a total of 4 hours. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool as described in detail by de la Llera-Moya et al (de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. PMID: 20075420). (NCT01156597)
Timeframe: 24 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Pioglitazone Group | 1.02 |
| Comparator Group | 1.05 |
Lipoproteins will be isolated and analyzed using the gradient ultracentrifugation-high pressure liquid chromatography technique to isolate very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) subfractions. Protein and lipid compositions of HDL is determined (NCT01156597)
Timeframe: 24 weeks
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| HDL-apoAI at end point | HDL-apoAII at end point | HDL-apoCI at end point | HDL-apoCII at end point | HDL-apoCIII at end point | HDL-apoM at end point | |
| Comparator Group | 65.7 | 22.6 | 8.4 | 2.8 | 12.5 | 0.43 |
| Pioglitazone Group | 65.0 | 26.6 | 10.9 | 3.5 | 11.8 | 0.62 |
"The primary endpoint will be increased high density lipoprotein cholesterol and decreased triglycerides measured as the difference after 12 or 24 weeks of treatment from baseline levels. The data are expressed as the percent change from the baseline value and calculated using he equation:~Change=[100%*(Endpoint value - Baseline Value)/Baseline Value]" (NCT01156597)
Timeframe: 24 weeks
| Intervention | % Change (Mean) | |||
|---|---|---|---|---|
| % Change in HDL cholesterol at 12 weeks | % Change in HDL cholesterol at 24 weeks | % Change in triglycerides at 12 weeks | % Change in triglycerides at 24 weeks | |
| Comparator Group | 2.7 | -1.5 | 7.4 | 19.7 |
| Pioglitazone Group | 7.9 | 15.7 | -10.9 | -15.4 |
64 reviews available for troglitazone and Insulin Resistance
| Article | Year |
|---|---|
[Insulin resistance in myotonic dystrophy].
Topics: Chromans; Humans; Hyperinsulinism; Insulin Resistance; Insulin-Like Growth Factor I; Myotonic Dystro | 2002 |
[Uric acid metabolism and insulin resistance in type 2 diabetes].
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resista | 2002 |
Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
Topics: Adipose Tissue; Animals; Chromans; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies | 2002 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ins | 2002 |
[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug T | 2002 |
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem | 2003 |
Insulin sensitizers for polycystic ovary syndrome.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2003 |
Effects of the thiazolidinediones on cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypoglyc | 2002 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
[Progress in the prevention of type 2 diabetes].
Topics: Acarbose; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Chromans | 2003 |
Cardiovascular and sympathetic effects of reversing insulin resistance in hypertension.
Topics: Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Sympathetic Nervous System; | 2004 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
Management of the metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di | 2005 |
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2007 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose | 1995 |
Effects of troglitazone on insulin sensitivity.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Gl | 1996 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase | 1996 |
Troglitazone: a new antihyperglycemic agent.
Topics: Chromans; Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistanc | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
[Adipocyte differentiation and nuclear receptor].
Topics: Adipocytes; Cell Differentiation; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin | 1997 |
[Insulin, as a regulating factor of blood pressure].
Topics: Animals; Cell Division; Chromans; Humans; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insuli | 1997 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
[Oral hypoglycemic agents--overview].
Topics: Acarbose; Administration, Oral; Biguanides; Chromans; Glycoside Hydrolase Inhibitors; Humans; Hypogl | 1997 |
[Measures to meet the side effects of the orally administered antihyperglycemic drugs].
Topics: Acarbose; Administration, Oral; Animals; Biguanides; Cardiovascular System; Chromans; Drug Interacti | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrola | 1997 |
Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Topics: Animals; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Glucose Intolerance; Humans; Hypogly | 1998 |
[Thiazolidindiones in type II diabetes mellitus].
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dru | 1998 |
Learning to use troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thi | 1998 |
Thiazolidinediones--tools for the research of metabolic syndrome X.
Topics: Antioxidants; Blood Vessels; Chromans; Humans; Hypoglycemic Agents; Insulin Resistance; Microvascula | 1998 |
New therapeutic approaches to reversing insulin resistance.
Topics: Animals; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypogly | 1998 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
Troglitazone. Is it all over?
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine | 1999 |
Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resi | 1999 |
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Topics: Antioxidants; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; C | 1999 |
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angio | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 1999 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellit | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, | 2000 |
[Troglitazone].
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic | 2000 |
[Insulin sensitizer and hypertension].
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Chromans; Humans; Hyperinsulinism; Hypertension; Hypogl | 2000 |
[Dyslipidemia in insulin resistance and its improvement by troglitazone].
Topics: Cholesterol, HDL; Chromans; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Thiazo | 2000 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; H | 2000 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellit | 2000 |
[Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
Topics: Animals; Chromans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2000 |
[Troglitazone for treatment of polycystic ovary syndrome].
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Thiazo | 2000 |
[Insulin resistance induced by drugs or agents].
Topics: Animals; Antihypertensive Agents; Benzothiadiazines; Chromans; Contraceptives, Oral; Diuretics; Gluc | 2000 |
[Thiazolidinediones].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag | 1999 |
New agents for Type 2 diabetes.
Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglyce | 1999 |
[PPAR gamma and thiozolidinedione derivatives as an antidiabetic drug for treating insuline resistance].
Topics: Animals; Chromans; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Receptors, | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.
Topics: Chromans; Clinical Trials as Topic; Glucose; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin R | 2000 |
Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Mice | 2000 |
[Insulin-sensitizing agents and hypertension].
Topics: Animals; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thia | 2000 |
Troglitazone and related compounds: therapeutic potential beyond diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
The polycystic ovary syndrome: treatment with insulin sensitizing agents.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Ovar | 1999 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimeri | 2001 |
[Lipodystrophia].
Topics: Animals; Cardiomyopathy, Hypertrophic; Chromans; Diabetes Mellitus; Diagnosis, Differential; Fatty L | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship | 2001 |
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing | 2002 |
37 trials available for troglitazone and Insulin Resistance
| Article | Year |
|---|---|
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Double-Blind Method; Female; Gluc | 2002 |
Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
Topics: Adult; Chromans; Dexamethasone; Drug Interactions; Energy Metabolism; Fatty Acids, Nonesterified; Fe | 2002 |
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
Topics: Blood Glucose; Blood Pressure; Chromans; Endothelium, Vascular; Female; Humans; Hyperandrogenism; Hy | 2003 |
Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.
Topics: Adult; Aged; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fe | 2003 |
Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
Topics: Adult; Aorta; Blood Flow Velocity; Blood Pressure; Cardiovascular Diseases; Chromans; Diabetes Melli | 2003 |
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Blood Glucose; Chromans; Dehydroepiandrosterone Sulfate; Dose-Response Relati | 2003 |
The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
Topics: Adult; Black People; Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Chromans; Diabete | 2003 |
Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Chromans; Female; Humans; Hyperlipidemias; Hypoglycemic A | 2003 |
Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
Topics: Blood Glucose; C-Reactive Protein; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2004 |
Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hispanic or | 2004 |
Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension.
Topics: Antihypertensive Agents; Blood Glucose; Chromans; Female; Heart; Humans; Hypertension; Hypertrophy, | 2004 |
Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
Topics: Adult; Arteriosclerosis; Carotid Arteries; Chromans; Diabetes Mellitus, Type 2; Disease Progression; | 2005 |
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypoglycemic Agen | 2005 |
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.
Topics: Adult; Aged; Biopsy; Blood Glucose; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Female | 2006 |
Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.
Topics: Blood Glucose; Body Weight; C-Peptide; Cell Adhesion Molecules; Chromans; Diabetes Mellitus, Type 2; | 2006 |
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
Topics: Aged; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Female; Heart Rate; Hemogl | 1995 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Chromans; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Double-Bli | 1996 |
Leptin concentrations in the polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Chromans; Double-Blind Method; Female; Humans; Hyperinsulinism; Hypoglycemic | 1997 |
Efficacy of troglitazone measured by insulin resistance index.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; | 1997 |
Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Topics: Administration, Oral; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Chromans; Diabetes Mel | 1997 |
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Do | 1998 |
Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relations | 1998 |
Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.
Topics: Adult; Blood Glucose; Body Weight; Cholesterol, LDL; Chromans; Cross-Over Studies; Double-Blind Meth | 1998 |
Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Topics: Acetylcholine; Adult; Analysis of Variance; Biomarkers; Blood Glucose; Cardiovascular System; Case-C | 1998 |
Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients.
Topics: Blood Glucose; Body Mass Index; Chromans; Diabetes Mellitus, Type 2; Energy Intake; Feeding Behavior | 1998 |
Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Chromans; | 1998 |
Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.
Topics: Adult; Androgens; Chromans; Female; Gonadotropins; Hormones; Humans; Hypoglycemic Agents; Insulin; I | 1999 |
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 1999 |
Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.
Topics: Aged; Chromans; Coronary Disease; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypogly | 1999 |
Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Topics: Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Ag | 1999 |
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus; HIV | 2000 |
Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.
Topics: Adipose Tissue; Adult; Aged; Body Composition; Chemical and Drug Induced Liver Injury; Child; Chroma | 2000 |
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gona | 2001 |
Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Blood Glucose; Case-Control Studies; Chromans; Coronary Circulation; D | 2001 |
Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin | 2001 |
Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
Topics: Aged; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Ac | 2002 |
119 other studies available for troglitazone and Insulin Resistance
| Article | Year |
|---|---|
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Topics: Animals; Blood Glucose; COS Cells; Cricetinae; Diabetes Mellitus; Hyperglycemia; Hypertriglyceridemi | 1996 |
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentia | 2012 |
Polypharmacology of N
Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Adiponectin; Animals; | 2017 |
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR | 2018 |
Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments.
Topics: Adipogenesis; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; M | 2019 |
A New Agonist for Peroxisome Proliferation-activated Receptor γ (PPARγ), Fraglide-1 from Zhenjiang Fragrant Vinegar: Screening and Characterization Based on Cell Culture Experiments.
Topics: 4-Butyrolactone; Acetic Acid; Animals; Anti-Obesity Agents; Cells, Cultured; Chlorocebus aethiops; C | 2017 |
Role of insulin resistance in the pathogenesis and development of type 2 diabetes in WBN/Kob-Lepr(fa) rats.
Topics: Age Factors; Animals; Area Under Curve; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; | 2013 |
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty A | 2015 |
Insulin resistance directly contributes to androgenic potential within ovarian theca cells.
Topics: Androgens; Animals; Cell Culture Techniques; Chromans; Female; Glucose Transporter Type 4; Insulin R | 2009 |
Palmitate-induced down-regulation of sortilin and impaired GLUT4 trafficking in C2C12 myotubes.
Topics: ADAM Proteins; ADAM17 Protein; Adaptor Proteins, Vesicular Transport; Animals; Cell Line; Chromans; | 2010 |
Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23.
Topics: Adipocytes; Adipogenesis; Arrhythmias, Cardiac; Body Mass Index; Cell Line; Chromans; Chromosomes, H | 2012 |
Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Blood Flow Velocity; Blood Glucose; Carotid Arteries; Catheterization; Cell Division; Chrom | 2002 |
Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Body Weight; Caloric Restriction; Chroma | 2002 |
Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats.
Topics: Adipose Tissue; Animals; Cell Fractionation; Chromans; Diabetes Mellitus; Disease Models, Animal; Hy | 2002 |
Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo.
Topics: Adipose Tissue; Animals; Chromans; Esterification; Fasting; Fatty Acids, Nonesterified; Glycerol; Hy | 2003 |
Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding.
Topics: Aging; Animals; Chromans; Dietary Fats; Heterozygote; Insulin Resistance; Metabolism, Inborn Errors; | 2003 |
Differences in troglitazone action on glucose metabolism in freshly isolated vs long-term incubated rat skeletal muscle.
Topics: Animals; Cells, Cultured; Chromans; Glucose; Glycogen; In Vitro Techniques; Incubators; Insulin; Ins | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids | 2003 |
Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome.
Topics: Adult; Cells, Cultured; Chromans; DNA; Female; Glucose; Granulosa Cells; Humans; Insulin; Insulin Re | 2003 |
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistan | 2004 |
Preventing the progression of diabetes mellitus.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents; Inf | 2005 |
Effect of troglitazone on the desaturases in a rat model of insulin-resistance induced by a sucrose-rich diet.
Topics: Animals; Chromans; Dietary Carbohydrates; Disease Models, Animal; Fatty Acid Desaturases; Insulin Re | 2005 |
Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Chromans; Diabetes Mellitus, Type | 2005 |
Insulin resistance contributes to obesity-related proteinuria.
Topics: Adult; Biopsy; Blood Glucose; Blood Pressure; Body Mass Index; Chromans; Creatinine; Female; Follow- | 2005 |
Effect of troglitazone on the excess testosterone and LH secretion in thyroidectomized, insulin-resistant, type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Cells, Cultured; Chorionic Gonadotropin; Chromans; Diabetes Mellitus, Type 2; Female; Gene | 2005 |
Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Chromans; Complement C1q; Complement C1r; Complement C1s; Com | 2007 |
A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
Topics: Adipocytes; Body Fat Distribution; Cell Differentiation; Chromans; Humans; Insulin Resistance; Lamin | 2007 |
Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes.
Topics: Adipocytes; Adiponectin; Cell Differentiation; Chromans; Culture Media, Conditioned; Female; Glycoge | 2007 |
The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cells, Cultured; Chromans; Humans; Insulin | 2008 |
Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
Topics: Animals; Blood Pressure; Body Weight; Chromans; Dietary Fats; Eating; Glucose; Glucose Clamp Techniq | 1995 |
Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Line; Chromans; Fibroblasts; Glucose; H | 1994 |
New directions in treating insulin resistance.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 1995 |
Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Gluco | 1993 |
Insulin resistance and the prevention of diabetes mellitus.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Re | 1994 |
Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Fructose; Glucose Clamp Technique; Hypoglycemic Ag | 1994 |
Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; | 1994 |
Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Glucose; Homeostasis; Hypertension; Insulin; Insul | 1994 |
Antihypertensive effects of CS-045 treatment in obese Zucker rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Chromans; Diuresis; Fe | 1993 |
A study of effect of CS-045, a new antidiabetic drug, on hypertension in spontaneously hypertensive rat.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Hypertension; Hypoglycemic Agents; Insulin; Insuli | 1995 |
Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
Topics: Aging; Animals; Blood Glucose; Body Weight; Chromans; Fructose; Hyperinsulinism; Hypoglycemic Agents | 1995 |
A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1996 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 1997 |
Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucose; Glucose Clamp | 1997 |
Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis.
Topics: Animals; Blood Glucose; Chromans; Disease Models, Animal; Fasting; Female; Glucose Tolerance Test; H | 1997 |
New diabetes drug targets insulin resistance.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thi | 1997 |
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Chromans; Female; Fibrinolysis; Glucose; Glucose Tolerance Test; Gonadotropins; Hu | 1997 |
Troglitazone ameliorates insulin resistance in patients with Werner's syndrome.
Topics: Adult; Blood Glucose; Chromans; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin | 1997 |
Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Blood Pressure; Chromans; Female; Heart Rate; Hyperlipidemias; Insulin; Insulin Resistance; | 1997 |
TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Chromans; Fatty Acids, Nonesterified; Glucose Clamp | 1997 |
Troglitazone action is independent of adipose tissue.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type | 1997 |
Troglitazone action is independent of adipose tissue.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type | 1997 |
Troglitazone action is independent of adipose tissue.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type | 1997 |
Troglitazone action is independent of adipose tissue.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type | 1997 |
Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle.
Topics: Adipose Tissue; Animals; Cell Line; Chromans; Gene Expression Regulation; Hypoglycemic Agents; Insul | 1998 |
Thiazolidinediones and their effects on glucose transporters.
Topics: Animals; Chromans; Gene Expression Regulation; Glucose; Hypoglycemic Agents; Insulin Resistance; Mon | 1997 |
Effects of troglitazone on dexamethasone-induced insulin resistance in rats.
Topics: Animals; Blood Glucose; Chromans; Dexamethasone; Glucocorticoids; Glucose; Glucose Clamp Technique; | 1998 |
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Topics: Adipocytes; Adipose Tissue; Animals; Apoptosis; Blood Glucose; Blotting, Northern; Body Weight; Chro | 1998 |
Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance.
Topics: Administration, Oral; Animals; Blood Glucose; Chromans; Cohort Studies; Glucosamine; Glucose Clamp T | 1998 |
Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats.
Topics: Animals; Catheterization; Cell Division; Cells, Cultured; Chromans; DNA; Endothelium, Vascular; Insu | 1998 |
Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells.
Topics: Aorta; Arteriosclerosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Culture | 1998 |
Insulin-sensitising agents in polycystic-ovary syndrome.
Topics: Chromans; Controlled Clinical Trials as Topic; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; | 1998 |
Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats.
Topics: Administration, Oral; Animals; Chromans; Glucose; Glucose Clamp Technique; Human Growth Hormone; Hyp | 1998 |
Troglitazone and small low-density lipoprotein in type 2 diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, | 1998 |
Ways of changing sensitivity to insulin.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thi | 1997 |
Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes.
Topics: Adipocytes; Animals; Biological Transport; Cell Differentiation; CHO Cells; Chromans; Cricetinae; En | 1998 |
Troglitazone reduces free fatty acid-induced insulin resistance in perfused rat hindquarter.
Topics: Animals; Chromans; Fatty Acids, Nonesterified; Hindlimb; Hypoglycemic Agents; Insulin; Insulin Resis | 1998 |
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intoleran | 1998 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vess | 1999 |
Complementary measures for promoting insulin sensitivity in skeletal muscle.
Topics: Adipocytes; Animals; Chromans; Chromium; Fatty Acids, Nonesterified; Fish Oils; Humans; Hypoglycemic | 1998 |
Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione.
Topics: Animals; Chromans; Gene Expression Regulation, Enzymologic; Glucose; Glucose Clamp Technique; Glucos | 1999 |
Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy.
Topics: Adult; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Myotonic Dystrophy; Thiazo | 1999 |
Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Topics: Animals; Blood Glucose; Blood Pressure; Catecholamines; Chromans; Diabetes Mellitus, Type 2; Glucose | 1999 |
Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome.
Topics: Acanthosis Nigricans; Adult; Blood Glucose; Chromans; Female; Gonadal Steroid Hormones; Humans; Hypo | 1999 |
Effects of troglitazone on substrate storage and utilization in insulin-resistant rats.
Topics: Animals; Body Weight; Chromans; Eating; Glucose; Glycogen; In Vitro Techniques; Insulin; Insulin Res | 1999 |
Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; | 1999 |
Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and in
Topics: Animals; Chromans; Guanidines; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; | 1999 |
Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.
Topics: Angina Pectoris, Variant; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Humans; Insulin Re | 1999 |
Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone.
Topics: Androstenedione; Animals; Blood Glucose; Body Composition; Chromans; Dehydroepiandrosterone; Diabete | 1999 |
Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats.
Topics: Animals; Chromans; Glucosamine; Glucose Clamp Technique; Hypoglycemic Agents; Inositol; Insulin Resi | 1999 |
A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance.
Topics: Chromans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Assessment of human muscle glycogen synthesis and total glucose content by in vivo 13C MRS.
Topics: Adult; Carbon Isotopes; Chromans; Glucose; Glucose Clamp Technique; Glycogen; Humans; Hypoglycemic A | 2000 |
Troglitazone improves recovery of left ventricular function after regional ischemia in pigs.
Topics: Animals; Blood Pressure; Chromans; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Oxy | 2000 |
Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes.
Topics: 3T3 Cells; Abortifacient Agents, Steroidal; Adipocytes; Animals; Binding Sites; Chromans; Dexamethas | 2000 |
Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats.
Topics: Animals; Chromans; Dexamethasone; Drug Combinations; Glucocorticoids; Glucose; Glucose Clamp Techniq | 2000 |
Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
Topics: Androgen Antagonists; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2000 |
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Topics: Adult; Arteriosclerosis; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; G | 2000 |
[Troglitazone, an insulin action enhancer--a drug of precision to treat adult-onset diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thi | 1997 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug | 2000 |
[A 75-year-old type 2 diabetes mellitus case responding strikingly troglitazone: possible mechanism of insulin resistance induced by insulin antibody].
Topics: Aged; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Antibodies; | 2000 |
Lipoatrophy, lipodystrophy, and insulin resistance.
Topics: Body Composition; Chromans; Diabetes Mellitus, Lipoatrophic; Humans; Hypoglycemic Agents; Insulin Re | 2000 |
Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Eating; Fluorenes; Gene Expression; Glucose Tolerance | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin | 2000 |
Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Chromans; Diet, Reducing; Female; Humans; Hypertension; Hypoglycemic Ag | 2000 |
Glucose modifies the cross-talk between insulin and the beta-adrenergic signalling system in vascular smooth muscle cells.
Topics: Animals; Cells, Cultured; Chromans; Glucose; Insulin; Insulin Receptor Substrate Proteins; Insulin R | 2000 |
Renal protective effect of troglitazone in Wistar fatty rats.
Topics: Animals; Blood Pressure; Body Weight; Chromans; Female; Hypoglycemic Agents; Insulin Resistance; Kid | 2000 |
UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats.
Topics: Animals; Antioxidants; Body Weight; Carbon Dioxide; Carrier Proteins; Chromans; Diabetes Mellitus, T | 2000 |
Dietary fat-induced increase in blood pressure and insulin resistance in rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Body Weight; Chromans; Dietary Carbohydrates | 2000 |
Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.
Topics: Adipocytes; Base Sequence; Biomarkers; Cell Differentiation; Cells, Cultured; Chromans; Diabetes Mel | 2001 |
Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobi | 2000 |
Dehydroepiandrosterone suppresses elevated hepatic glucose-6-phosphatase mRNA level in C57BL/KsJ-db/db mice: comparison with troglitazone.
Topics: Animals; Blood Glucose; Blotting, Northern; Body Weight; Chromans; Dehydroepiandrosterone; Diabetes | 2000 |
Insulin resistance and nonalcoholic steatohepatitis: fat or fiction?
Topics: Chromans; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Thiazoles; Thiazo | 2001 |
Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Chromans; Humans; Hypertension; H | 2001 |
Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats.
Topics: Aging; Amylases; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fibrosis; Homeostasis; | 2001 |
Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
Topics: Administration, Oral; Blood Glucose; Chromans; Dexamethasone; Glucose Tolerance Test; Humans; Hypogl | 2001 |
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Topics: Animals; Antihypertensive Agents; Base Sequence; Chromans; Disease Models, Animal; DNA Primers; Glom | 2001 |
Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats.
Topics: Animals; Chromans; Fatty Acids, Nonesterified; Fructose; Hypoglycemic Agents; Insulin Resistance; Le | 2001 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric | 2001 |
Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fluorodeoxyg | 2001 |
Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Dietary Fats; Female; Glucose; Glucose Clamp Techniqu | 2001 |
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
Topics: Adult; Arteriosclerosis; Brachial Artery; Case-Control Studies; Chromans; Endothelium, Vascular; Glu | 2000 |
A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance.
Topics: Animals; Antioxidants; Blood Glucose; Blood Pressure; Chromans; Disease Models, Animal; Fatty Acids; | 2001 |
Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s).
Topics: Animals; Autoradiography; Carcinoma, Hepatocellular; Chromans; Diabetes Mellitus, Type 2; Hypoglycem | 2001 |
Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
Topics: Animals; Chromans; Cycloheximide; Dactinomycin; Drug Interactions; Energy Metabolism; Gene Expressio | 2001 |
Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats.
Topics: Animals; CD36 Antigens; Chromans; Emulsions; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; | 2001 |
Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Chro | 2001 |
A treatment for Mr WP: thiazolidinediones after troglitazone.
Topics: Aged; Animals; Body Mass Index; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hem | 2002 |
C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Blotting, Western; Chromans; Cy | 2002 |
Troglitazone stimulates pancreatic growth in normal rats.
Topics: Aging; Alanine Transaminase; Amylases; Animals; Aspartate Aminotransferases; Blood Glucose; Body Wei | 2002 |
The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats.
Topics: Animals; Chromans; Cystathionine beta-Synthase; Erythrocytes; Female; Homocysteine; Hypoglycemic Age | 2002 |
Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Arteriosclerosis; Cell Division; Cells, Cultured; Chromans; Depression, Che | 2002 |
Pharmacological treatments for GH-induced insulin resistance.
Topics: Animals; Blood Gas Analysis; Blood Glucose; Chromans; Drug Interactions; Human Growth Hormone; Hypog | 1999 |
Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Topics: Adipose Tissue; Animals; Benzopyrans; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus, Expe | 1988 |